1,752 Shares in GSK plc (NYSE:GSK) Bought by CoreFirst Bank & Trust

CoreFirst Bank & Trust acquired a new position in shares of GSK plc (NYSE:GSK) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,752 shares of the pharmaceutical company’s stock, valued at approximately $59,000.

Other large investors have also recently bought and sold shares of the company. Primecap Management Co. CA raised its position in GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock valued at $854,349,000 after purchasing an additional 10,407,905 shares in the last quarter. FMR LLC raised its holdings in shares of GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Mondrian Investment Partners LTD raised its holdings in shares of GSK by 17.6% during the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock worth $205,920,000 after buying an additional 874,004 shares in the last quarter. Hotchkis & Wiley Capital Management LLC lifted its position in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after buying an additional 833,080 shares during the last quarter. Finally, Miller Howard Investments Inc. NY bought a new position in GSK in the fourth quarter valued at about $23,366,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GSK has been the subject of a number of research reports. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Trading Up 0.2 %

GSK opened at $38.65 on Wednesday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93. The company’s 50 day moving average price is $36.90 and its two-hundred day moving average price is $36.80. The firm has a market capitalization of $80.00 billion, a price-to-earnings ratio of 24.31, a PEG ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, research analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.07%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio (DPR) is 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.